ES2542328T3 - Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma - Google Patents

Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma Download PDF

Info

Publication number
ES2542328T3
ES2542328T3 ES03796633.0T ES03796633T ES2542328T3 ES 2542328 T3 ES2542328 T3 ES 2542328T3 ES 03796633 T ES03796633 T ES 03796633T ES 2542328 T3 ES2542328 T3 ES 2542328T3
Authority
ES
Spain
Prior art keywords
markers
expression
protein
marker
prediction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03796633.0T
Other languages
English (en)
Spanish (es)
Inventor
George Mulligan
Barbara M. Bryant
Michael P. Morrissey
Andrew Bolt
Andrew I. Damokosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32507743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2542328(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2542328T3 publication Critical patent/ES2542328T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
ES03796633.0T 2002-12-06 2003-12-04 Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma Expired - Lifetime ES2542328T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43151402P 2002-12-06 2002-12-06
US431514P 2002-12-06
PCT/US2003/038539 WO2004053066A2 (en) 2002-12-06 2003-12-04 Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy

Publications (1)

Publication Number Publication Date
ES2542328T3 true ES2542328T3 (es) 2015-08-04

Family

ID=32507743

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03796633.0T Expired - Lifetime ES2542328T3 (es) 2002-12-06 2003-12-04 Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma

Country Status (8)

Country Link
US (3) US20040156854A1 (cg-RX-API-DMAC7.html)
EP (1) EP1581629B1 (cg-RX-API-DMAC7.html)
JP (2) JP5717937B2 (cg-RX-API-DMAC7.html)
AU (1) AU2003298873B2 (cg-RX-API-DMAC7.html)
CA (1) CA2508348C (cg-RX-API-DMAC7.html)
ES (1) ES2542328T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA05005923A (cg-RX-API-DMAC7.html)
WO (1) WO2004053066A2 (cg-RX-API-DMAC7.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050836A1 (en) * 1998-05-01 2008-02-28 Isabelle Guyon Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20090215058A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
US20090226915A1 (en) * 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
US20090215024A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Biomarkers upregulated in prostate cancer
AU2003300899A1 (en) * 2002-12-12 2004-06-30 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
AU2005222934B2 (en) * 2004-03-12 2010-06-17 Entremed, Inc. Antiangiogenic agents
EP1766086A4 (en) 2004-05-21 2009-10-28 Univ Arkansas USE OF GENETIC EXPRESSION PROFILING TO PREVENT THE CHANCE OF SURVIVAL OF A PATIENT WITH CANCER
WO2006053328A2 (en) * 2004-11-12 2006-05-18 Health Discovery Corporation Biomarkers for screening, predicting, and monitoring prostate disease
WO2006101535A1 (en) * 2005-03-23 2006-09-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of proteasome function to potentiate the proapoptotic and antitumor activity of cytokines
JP4887505B2 (ja) * 2005-04-18 2012-02-29 国立大学法人浜松医科大学 癌の転移性及び浸潤能の検査方法
EP2687608B1 (en) * 2005-06-08 2017-02-08 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
WO2007002972A2 (en) * 2005-07-06 2007-01-11 Biodevelops Pharma Entwicklung Gmbh Use of a compound for enhancing the expression of membrane proteins on the cell surface
WO2007022041A2 (en) * 2005-08-11 2007-02-22 Novartis Ag Mutations and polymorphisms of hdac3
EP1946114A4 (en) * 2005-09-21 2010-05-26 Ccc Diagnostics Llc COMPREHENSIVE DIAGNOSTIC TESTS FOR PERSONAL ANTIBODY CHEMOTHERAPY (PAC)
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
CA2632188A1 (en) * 2005-11-10 2007-05-24 Rosetta Inpharmatics Llc Discover biological features using composite images
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
CN100372568C (zh) * 2005-12-09 2008-03-05 中国科学院广州生物医药与健康研究院 化合物mg-132在制备治疗白血病药物中的应用
US7875274B2 (en) * 2005-12-16 2011-01-25 The Board Of Trustees Of The Leland Stanford Junior University Protein modulators of resistance to alkylating agents
US20070292869A1 (en) * 2006-03-02 2007-12-20 Ppd Biomarker Discovery Sciences, Llc Compositions and Methods for Analyzing Renal Cancer
US8399440B2 (en) * 2006-03-20 2013-03-19 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
WO2007128884A1 (en) * 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
WO2008021183A2 (en) * 2006-08-10 2008-02-21 Millennium Pharmaceuticals, Inc. For the identification, assessment, and treatment of patients with cancer therapy
CA2667348A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma
JP5413818B2 (ja) * 2007-03-29 2014-02-12 国立大学法人佐賀大学 蛍光多重染色による蛋白定量法
EP2155231B1 (en) * 2007-04-10 2012-08-08 The Johns Hopkins University Imaging and therapy of virus-associated tumors
US20080317768A1 (en) * 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
CA2693310C (en) 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
CA2706881A1 (en) * 2007-11-30 2009-06-11 Brian Z. Ring Tle3 as a marker for chemotherapy
WO2009076551A2 (en) * 2007-12-12 2009-06-18 The Regents Of The University Of California Systems and methods for predicting response of biological samples
US20100086922A1 (en) * 2008-05-30 2010-04-08 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment
US8321144B2 (en) * 2008-10-23 2012-11-27 Microsoft Corporation Non-contiguous regions processing
EP2722400A3 (en) * 2008-10-29 2014-07-09 William Beaumont Hospital Methods of using biomarkers
CN102361991A (zh) * 2009-01-02 2012-02-22 阿肯色大学托管委员会 硼替佐米在预测多发性骨髓瘤患者生存率中的应用
US9107935B2 (en) * 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US20110207144A1 (en) * 2009-08-21 2011-08-25 Derek Marshall In vitro screening assays
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
CA2771702A1 (en) * 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
RU2012110580A (ru) * 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Способы скрининга in vivo
MX2012002271A (es) * 2009-08-21 2012-07-20 Gilead Biologics Inc Metodos y composiciones terapeuticas.
WO2011060179A1 (en) * 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
EP2531616A4 (en) * 2010-02-03 2013-07-10 Univ Monash DIAGNOSIS AND FORECAST ASSAY FOR BREAST CANCER
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
JP5740880B2 (ja) 2010-09-15 2015-07-01 株式会社リコー 画像形成装置、及びプログラム
HRP20160851T1 (hr) 2011-08-11 2016-09-23 Janssen Pharmaceutica N.V. Prediktori za liječenje karcinoma
EP2776586B1 (en) * 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013148147A1 (en) 2012-03-26 2013-10-03 The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
WO2014078571A1 (en) * 2012-11-14 2014-05-22 The Board Of Trustees Of The University Of Arkansas Methods of detecting 14q32 translocations
EP2999796B1 (en) 2013-05-20 2017-10-25 BioVentures, LLC Gep5 model for multiple myeloma
ES2738289T3 (es) 2013-11-06 2020-01-21 Hospital Clinic Barcelona Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión
JP6675990B2 (ja) * 2014-05-20 2020-04-08 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 多発性骨髄腫の治療方法
US10607152B2 (en) 2015-05-26 2020-03-31 Textio, Inc. Using machine learning to predict outcomes for documents
US20170159130A1 (en) * 2015-12-03 2017-06-08 Amit Kumar Mitra Transcriptional classification and prediction of drug response (t-cap dr)
JP6788020B2 (ja) 2015-12-30 2020-11-18 コリア シップビルディング アンド オフショア エンジニアリング カンパニー リミテッド 液化ガス運搬船
ES2859423T3 (es) 2016-04-20 2021-10-04 Us Health Evaluación del linfoma de células del manto y procedimientos relacionados con el mismo
CN106928370B (zh) * 2016-09-26 2021-02-02 华东师范大学 一种REGγ-20S蛋白酶体抑制剂的筛选系统及其应用
US11804298B2 (en) 2017-07-17 2023-10-31 Joon Kim Cancer diagnostic apparatus and cancer diagnostic system using the same
KR102007664B1 (ko) * 2017-07-17 2019-08-07 김준 암 진단기 및 이를 이용한 암 진단시스템
WO2019040757A1 (en) * 2017-08-23 2019-02-28 The General Hospital Corporation MULTIPLEXED PROTEOMIC AND PREDICTIVE EVALUATION OF CANDIDATE MEDICINE
EP3502279A1 (en) * 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
US12433488B2 (en) * 2018-01-17 2025-10-07 14336186 Canada Corp. (Exclaro) System and methods for real time raman spectroscopy for cancer detection
CN110499287B (zh) * 2019-08-30 2021-07-23 博雅干细胞科技有限公司 简易制备胎盘间充质干细胞外泌体的方法
US20230340604A1 (en) * 2022-04-20 2023-10-26 Morehouse School Of Medicine Methods of treatment and diagnosis of multiple myeloma progression

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
HUT62312A (en) 1990-03-05 1993-04-28 Cephalon Inc Process for producing chymotrypsin-like proteases and their inhibitors
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
JP2003504023A (ja) * 1999-07-02 2003-02-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 新規gタンパク質共役受容体である16405受容体
AU2001239941A1 (en) * 2000-02-29 2001-09-12 The General Hospital Corporation Beta netrin and uses thereof
US20030185815A1 (en) * 2001-04-03 2003-10-02 Muralidhara Padigaru Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
US20040006205A1 (en) * 2001-04-03 2004-01-08 Li Li Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002092127A1 (en) * 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
EP2687608B1 (en) * 2005-06-08 2017-02-08 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers

Also Published As

Publication number Publication date
EP1581629A2 (en) 2005-10-05
JP5896593B2 (ja) 2016-03-30
AU2003298873B2 (en) 2011-09-01
AU2003298873A1 (en) 2004-06-30
JP2010207230A (ja) 2010-09-24
WO2004053066A2 (en) 2004-06-24
US20170023577A1 (en) 2017-01-26
MXPA05005923A (es) 2005-09-21
WO2004053066A3 (en) 2006-09-08
US20040156854A1 (en) 2004-08-12
JP2006517093A (ja) 2006-07-20
CA2508348A1 (en) 2004-06-24
EP1581629B1 (en) 2015-04-01
HK1086027A1 (en) 2006-09-08
US20090181393A1 (en) 2009-07-16
CA2508348C (en) 2016-07-12
JP5717937B2 (ja) 2015-05-13
EP1581629A4 (en) 2007-05-16

Similar Documents

Publication Publication Date Title
EP1581629B1 (en) Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
US9500656B2 (en) Methods for the identification, assessment, and treatment of patients with cancer therapy
ES2624863T3 (es) Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
ES2656487T3 (es) Evaluación de la respuesta a la terapia de neoplasmas neuroendocrinos gastroenteropancreáticas (GEP-NEN)
US20230160017A1 (en) Prediction of radiotherapy response for prostate cancer subject based on immune defense response genes
CN112501290B (zh) 与乳腺癌预后相关的标志分子以及检测试剂盒
Chen et al. Development and validation of nomogram with tumor microenvironment-related genes and clinical factors for predicting overall survival of endometrial cancer
CA2628390A1 (en) Molecular profiling of cancer
WO2011153345A2 (en) A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients
US20240182984A1 (en) Methods for assessing proliferation and anti-folate therapeutic response
US20150011411A1 (en) Biomarkers of cancer
HK1086027B (en) Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
US20240018602A1 (en) Polymorhpism detection for glioblastoma detection and treatment
Chen et al. Upregulation of B3GNT3 Correlates With Poor Prognosis and Decreased Immune Cell Infiltration In Pancreatic Adenocarcinoma
WO2019215394A1 (en) Arpp19 as biomarker for haematological cancers
HK1238302A (en) Dna methylation biomarker for early detection and risk assessment of cancer
HK1238302A1 (en) Dna methylation biomarker for early detection and risk assessment of cancer